CS
IONS icon

Credit Suisse’s Ionis Pharmaceuticals IONS Stock Holding History

Credit Suisse’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-85,000
Closed -$6.9M – 4174
2019
Q1 		$6.9M Sell
85,000
-15,000
-15% -$968K 0.01% 1473
2018
Q4 		$5.41M Buy
+100,000
New +$5.1M 0.01% 1521

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse's IONS Position: Q1 2024 in Review

Credit Suisse reduced its Ionis Pharmaceuticals (IONS) stake by 3.8% in Q1 2024, selling an estimated $344K and leaving 182,509 shares worth $7.91M. The position accounts for 0.01% of the portfolio, ranked #1039.

Credit Suisse first reported a position in IONS in Q2 2013 and has held it in 44 quarters since. The position peaked at $46.4M in Q2 2015. 362 funds tracked by Wall St. Rank hold IONS as of Q1 2024.

  • Credit Suisse held 182,509 shares of Ionis Pharmaceuticals worth $7.91M as of Q1 2024.
  • Credit Suisse sold 7,213 Ionis Pharmaceuticals shares in Q1 2024, an estimated $344K.
  • Ionis Pharmaceuticals made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #1039 holding.
  • Credit Suisse first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Ionis Pharmaceuticals position peaked at $46.4M in Q2 2015.
  • 362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.